|
Video: What is a Stock Split?
|
|
bluebird bio, Inc. is a biotechnology company. Co. is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell transfusions. According to our BLUE split history records, bluebird bio has had 2 splits. | |
|
bluebird bio (BLUE) has 2 splits in our BLUE split history database. The first split for BLUE took place on November 05, 2021. This was a 1544 for 1000 split, meaning for each 1000 shares of BLUE owned pre-split, the shareholder now owned 1544 shares. For example, a 1000 share position pre-split, became a 1544 share position following the split. BLUE's second split took place on December 13, 2024. This was a 1 for 20 reverse split, meaning for each 20 shares of BLUE owned pre-split, the shareholder now owned 1 share. For example, a 1544 share position pre-split, became a 77.2 share position following the split.
When a company such as bluebird bio splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. When a company such as bluebird bio conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the BLUE split history from start to finish, an original position size of 1000 shares would have turned into 77.2 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into bluebird bio shares, starting with a $10,000 purchase of BLUE, presented on a split-history-adjusted basis factoring in the complete BLUE split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/16/2014 |
|
End date: |
12/13/2024 |
|
Start price/share: |
$1,112.40 |
|
End price/share: |
$6.34 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.43% |
|
Average Annual Total Return: |
-40.35% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$57.03 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
11/05/2021 | 1544 for 1000 | 12/13/2024 | 1 for 20 |
|
|